IMV

IMV Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.740
-0.030
-1.69%
Closed 19:27 03/31 EDT
OPEN
1.850
PREV CLOSE
1.770
HIGH
1.850
LOW
1.590
VOLUME
176.05K
TURNOVER
--
52 WEEK HIGH
5.12
52 WEEK LOW
1.350
MARKET CAP
88.23M
P/E (TTM)
-4.1547
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IMV stock price target is 6.15 with a high estimate of 11.59 and a low estimate of 2.519.

EPS

IMV News

More
  • IMV, Inc. (IMV) CEO Frederic Ors on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 13h ago
  • Penny Stocks to Buy Using Technical Analysis for April 2020
  • Investopedia · 14h ago
  • IMV Inc. Announces Fourth Quarter and Full Year 2019 Financial and Operational Results
  • Business Wire · 1d ago
  • COVID-19 Vaccine Updates: J&J Identifies Lead Candidate, IMV Eyes Clinical Testing In Summer, Altimmune Partners With University Of Alabama
  • Benzinga · 1d ago

Industry

Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.25%

Hot Stocks

Symbol
Price
%Change

About IMV

IMV Inc. is a clinical-stage biopharmaceutical company focused on immunotherapy in oncology. The Company’s drug delivery platform (DPX) enables the programming of immune cells in vivo. The Company’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy combining DPX with a specific tumor target: Survivin. DPX-Survivac is a monotherapy in ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications.
More

Webull offers kinds of Imv Inc stock information, including NASDAQ:IMV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMV stock news, and many more online research tools to help you make informed decisions.